TRAIL-induced apoptosis: between tumor therapy and immunopathology

Corazza, Nadia; Kassahn, Daniela; Jakob, Sabine; Badmann, Anastasia; Brunner, Thomas (2009). TRAIL-induced apoptosis: between tumor therapy and immunopathology. Annals of the New York Academy of Sciences, 1171, pp. 50-58. Boston, Mass.: Blackwell 10.1111/j.1749-6632.2009.04905.x

Full text not available from this repository. (Request a copy)

The death ligand members of the tumor necrosis factor (TNF) family are potent inducers of apoptosis in a variety of cell types. In particular, TNF-related apoptosis-inducing ligand (TRAIL) has recently received much scientific and commercial attention because of its potent tumor cell-killing activity while leaving normal untransformed cells mostly unaffected. Furthermore, TRAIL strongly synergizes with conventional chemotherapeutic drugs in inducing tumor cell apoptosis, making it a most promising candidate for future cancer therapy. Increasing evidence indicates, however, that TRAIL may also induce or modulate apoptosis in primary cells. A particular concern is the potential side effect of TRAIL-based tumor therapies in the liver. In this review we summarize some of the recent findings on the role of TRAIL in tumor cell and hepatocyte apoptosis.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Service Sector > Institute of Pathology

UniBE Contributor:

Corazza, Nadia; Kassahn, Daniela; Badmann, Anastasia and Brunner, Thomas

ISSN:

0077-8923

ISBN:

19723037

Publisher:

Blackwell

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 15:08

Last Modified:

08 Jun 2016 10:49

Publisher DOI:

10.1111/j.1749-6632.2009.04905.x

PubMed ID:

19723037

Web of Science ID:

000269657300007

URI:

https://boris.unibe.ch/id/eprint/29967 (FactScience: 165537)

Actions (login required)

Edit item Edit item
Provide Feedback